Trial Profile
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Puma Biotechnology; Wyeth
- 19 Jul 2019 This trial has been completed in Bulgaria, according to European Clinical Trials Database
- 08 Feb 2019 This trial has been completed in United kingddom, as reported by European Clinical Trials Database.
- 11 Jul 2018 Status changed from active, no longer recruiting to completed.